INTRODUCTION
In the United States alone, pancreatic cancer is the 3rd leading cause of cancer death, accounting for over 50,000 cases annually, with a survival rate of less than 10% (1) . The most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), is often diagnosed at a late stage, limiting effective therapeutic interventions. Only 10-15% of patients are eligible for surgery, the only potentially curative option (2) . Although adjuvant chemotherapy has shown incremental improvements in resected patients, the vast majority recurs and succumbs to metastatic disease with a five year survival of only 1-2%. This poor survival underscores the need for novel tools to rapidly and precisely match patients with effective therapies.
The limited number of available preclinical PDAC models has been a major hurdle for discovery and translational research. Development of in vitro cell culture models, as well as transgenic and patient derived xenograft (PDX) mouse models, enables investigation of biological mechanisms and new treatments. However, traditional two-dimensional (2D) immortalized monolayer cell lines are limited, in that they do not reflect the variability or the structure of PDAC tumors. Primary cells cultured as monolayers do not reflect the heterogeneity of the primary tumor due to selection in culture, lack of stromal-stromal-cell communication, tissue-specific architecture and mechanical cues. Combined, these impact impact gene expression, which is key for modeling therapeutic responses (3) (4) (5) . Genetically-engineered mice, such as LSL-Kras G12D/+ ; LSL-Trp53 R172H/+ ; and Pdx-1-Cre are useful in that they are models of carcinogenesis within the pancreas, however they only represent very specific genetic mutations and fail to recapitulate the variability that is characteristic of PDAC (6) (7) (8) . Furthermore, PDX models have complex architecture and utilize heterogeneous patient tissue, but the clinical applicability is challenging due to prohibitive time requirements (up to 6 months to establish tumor growth), costs associated with in vivo systems, the large sample size required (~100 mm 3 ) , and the influence of infiltrating murine stromal cells on the tumor (9, 10) . The latter factor may influence the recent observations that the more times a PDX tumor is passaged through mice, the more transcriptionally "mouse-like" it becomes (11) . Due to the challenges related to existing systems, improved models of PDAC are essential.
Recently developed three-dimensional (3D) organoids may provide dramatic benefits compared to 2D cell culture and PDX models for their use in personalized medicine and drug discovery. Organoid models are rapidly and inexpensively developed from primary or metastatic tumor tissue for expansion and molecular profiling. Organoids also recapitulate biological features of a 3D environment, as demonstrated in pancreatic, colorectal, prostate and mammary cancers (12) (13) (14) (15) . Importantly, PDAC organoids can be grown with a high rate of success from very small amounts of tissue collected from diagnostic fine-needle biopsies (16, 17) , core needle biopsies, and in excisional intraoperative biopsies and these tissues are more likely to be passaged over time when grown in 3D versus 2D cultures (18) (19) (16) (17) .
Some barriers to the use of organoids in personalized therapies include lack of in-depth assessment of the histopathology, genetic stability, and molecular profiling of organoid models.
Comparisons are needed between organoids and primary tumors of origin, as well as among individual organoids derived from the same patient. Before organoids can be routinely employed as model systems more characterization of cellular and molecular properties are required.
Specifically, insufficient morphological characterization of organoids has been reported and comparisons are needed between organoids and primary tumors of origin, as well as among individual organoids derived from the same patient. Therefore, we performed histopathological profiling on organoid and PDX models for comparison to their corresponding primary tumors. In addition, we performed a thorough genomic characterization of organoid cultures by deep sequencing to determine if the models represent the genomic constitution of the primary tumor, and if they retain their genomic characteristics over time. We performed ex vivo drug testing to improve our understanding of the degree to which organoids model the therapeutic response of the corresponding tumor of origin. We have defined the histopathology, genetic heterogeneity and therapeutic sensitivity profiles of organoid models derived from PDAC patients as an initial effort to provide thorough pathological and genetic comparison between PDAC organoid models and the tumors from which they are derived.
MATERIAL AND METHODS

Human specimens
Between 2014 and 2017, 10 tumor samples were collected from patients with pancreatic cancer adenocarcinoma. The clinical information from those patients was collected (Supplementary Table 1 
Quantification of H&E architecture
A gastrointestinal pathologist scored architecture of tumor and organoids from H&E stained slides according to the three different patterns (Figure 1b 
Immunohistochemistry staining and quantification
Human samples, PDX and organoids were fixed with 10% formalin, paraffin embedded and sectioned (5µm 
RNASeq analysis pipeline
Sample specimens from tumors, normals and models from patients 1-4 and 7 were quantified using RNAseq. The cell lines in the multi-patient comparisons were sequenced using totalRNAseq with ribosome depletion (Illumina, MRZH11124), while FFPE derived tissue samples were sequenced using the RNAaccess capture kit from Illumina (RS-301-2001). All samples were quality checked and aligned using the following general outline: Reads from fastq files were adapter and quality-trimmed with a minimum phred score of 20 on 3' ends using cutadapt v 1.15 (21) and read quality was evaluated further using FastQC For differential expression, effective counts were used from eXpress output and similarly collapsed on gene name and limited to protein coding and lincRNA for patient 1 comparisons.
The R princomp and DESeq2 (23) libraries were used for differential gene expression analysis using the effective counts output from eXpress. PCA combined with linear regression was used to determine which covariates should be included in the final regression model for differential expression. In the set of samples used for multi-patient comparison, no significant covariates were identified besides the independent variable of interest. However, for the indepth analysis of patient 1, there was a detectable batch effect influencing principal component 1 (adjusted r squared 0.758, p-value 0.00028), and was included as a covariate in the general linear model using DESeq2. Genes were considered differentially expressed if they had an adjusted pvalue < 0.05 and a log2 fold change greater than 1 or less than -1. A representative subset of the top differentially expressed reads by adjusted p-value was generated by selecting the top 200 differentially expressed genes, defined as genes with the lowest adjusted p-value with a minimum mean coverage of 105.6608 from each biotype (tumor, PDX, 2D cell line, organoid).
The union of these top 200 genes, from each biotype was generated for a total of 518 unique genes that were considered in downstream analysis. The log2 fold change values from the genes in the union were extracted and any gene in the union that had an adjusted p-value > 0.05 in a particular biotype was not considered differentially expressed and therefore the log fold change was not taken into consideration for that biotype. For the multi-patient comparison, since sequencing was done over two lanes each for each patient, each lane was treated as a replicate to increase accuracy and power. Multiple runs were used in the in-depth analysis except for the PDX. Data from normal patient tissues in the study were combined and used as controls for all differential expression analyses.
Drop-Seq single cell RNA-Seq:
The single cell RNA-seq dataset is comprised of 15 separate drop-seq runs. For each run, a total of 2000 mature organoids were pooled, typsinized with TrypLE in presence of 10 µM Y-27632, strained into a single cell suspension and counted. The final concentration of the cell suspension varied between 100-120 cells/uL depending on the flow rate at which monodisperse droplets were formed. An aliquot from the cell suspension was stained with trypan blue to ensure high cell viability (>90%) at the time of establishing the cell preparation protocol. Organoids were harvested for drop-seq analysis at same growth size to ensure uniformity from run to run.
Nanoliter-sized droplets containing single cells and barcoded beads were prepared as described in Macosko et al. (24) . Briefly, droplets generated by co-flowing 1 mL each of cell and bead solutions through a microfluidic device were collected. The droplets were broken and the beads were collected and reverse-transcribed. The cDNA obtained was then PCR amplified and quantified. Finally, the cDNA was fragmentedand amplified using primers thatallow amplification of only the 3'ends, processed into RNA-seqlibraries and sequenced on the Illumina NextSeq 500 sequencer. The sequencing data was analyzed using the pipeline created by Macosko et. al. (24) to generate digital gene expression (DGE) matrices. Only cells with more than 250 genes were retained for subsequent clustering.
We developed a novel clustering approach based on a class of probabilistic generative models called topic models. In brief, the DGE is first normalized, scaled and log transformed.
The contribution of undesirable sources of variation such as cell cycle phase, batch effect and mitochondrial gene expression is assessed by calculating scores for each of these factors and regressed out of the data (25) . Next, a training set comprised of cells that express at least 900 genes is created and highly variable genes are identified (26) . A topic model is then generated from the training set using the highly variable genes as the vocabulary (27) . Then, a topic 
Statistical analysis, differential expression
For differentially expressed genes, R PCA package princomp was used to check for batch effects. In the set of samples used for multi-patient comparison, batch effects were negligible and therefore were not regressed out. However, for the in-depth analysis of patient 1, there was a detectable batch effect influencing principal component 1 (adjusted r squared 0.758), so it was 
Data availability
The genomic data from this publication has been deposited at www.ncbi.nlm.nih.gov. The submission ID is SUB4032998. The BioProject ID is PRJNA471134. Private login credentials are pending with the NIH.
RESULTS
Organoids from both primary PDAC and PDX share morphological features with the primary tumor
In order to generate clinically relevant PDAC models, benign and tumor tissue were collected at the time of surgical resection ( Table S1 ). PDAC organoids were grown from both PDX and primary tissue (15) . PDAC tumors from five patients were used to establish PDX tumors, followed by the growth of PDX-derived organoids from those xenografts. In addition, PDAC tumors from another five patients were utilized to grow primary tumor-derived organoids directly (without PDX) ( Figure S1 ).
To validate tumor pathology in PDX and organoid models, hematoxylin and eosin stain (H&E) histological analysis of uninvolved pancreas, primary tumor, PDX and organoid models was performed. A gastrointestinal pathologist compared the architecture and cell morphology in both PDX and organoid models to the primary tumors ( Figure 1A) . Benign ducts revealed simple columnar epithelium without significant cytological atypia, and areas of PDAC epithelium showed various degrees of architectural disorder and cytological atypia. Specifically, tumors from patients 3 and 5 ( Figure 1A) showed well differentiated tumor glands with small basally oriented nuclei and little or no cellular stratification. Tumor glands from patient 4 were slightly more atypical and demonstrated regions of stratification. Glands from patients 1 and 2
showed the greatest extent of cell atypia and cell stratification. We divided the architectural patterns of the organoids into three morphological classifications: simple, papillary, and solid/cribriform ( Figure 1C) . These architectures were quantified, and a high degree of correlation was observed between the morphological structure of the primary tumors and the corresponding organoids (R squared=0.67) (Figure 1D, left) . The architecture of the PDX models was more complex and atypical compared to the organoid models, in part due to the presence of mouse stroma within the tumor. Nevertheless, organoids derived from the PDX models recapitulated the microscopic features of the primary tumors.
To determine if organoids derived directly from the primary tumor also maintain tissue architecture similar to PDX-derived organoids, we grew organoids directly from the primary tumor (patients 6-10) and performed histological analysis of tissue derived from these five patients. We observed a similar glandular architecture between primary tumor and organoid models ( Figure 1B) . Like those derived from PDX passaged tumors, organoids derived directly from primary tumors maintained the morphological structure of their corresponding primary tumor. Specifically, the well-differentiated tumor glands seen in the organoids from patients 8 and 10 resembled the relatively simple glandular architecture observed in the primary tumors from these patients. Likewise, for patients 6, 7, and 9, the organoids demonstrated more cellular stratification akin to the primary tumors of these same patients. Quantitative analysis of glandular architecture demonstrated a high degree of morphological correlation between primary PDAC and organoids ( Figure 1D , right) (R squared=0.77).
Organoids and patient-derived tumor xenografts share protein expression features with corresponding primary tumors
To define the relevant protein expression profiles of the PDX and organoid models and to compare these protein expression patterns with both benign pancreatic and tumor tissue, we used a panel of immunohistochemical (IHC) markers. Since the majority of benign tissue obtained from the tumor resections demonstrated evidence of chronic pancreatitis, we also stained normal pancreatic samples selected from patients without PDAC and with no evidence of pancreatitis.
Cytokeratin markers 7 and 20 (CK7 and CK20) were selected to assess for pancreatic epithelial differentiation, and cellular tumor antigen p53 (p53), Claudin-4 and Cancer Antigen 19-9 (CA19-9) were selected due to their frequent expression in neoplastic pancreatic ductal epithelium (29-32) (Figure 2A, 2B) .
To quantify the extent that protein expression in the organoid and PDX models was recapitulated by the staining observed in the primary tumor, pixel count and intensity were measured for all cases. Cytokeratin proteins, normally found in the intracytoplasmic cytoskeleton of epithelial tissue, change their protein profile expression in PDAC. CK7 and CK19 are expressed in 90-100% of PDAC (33, 34) . In contrast, CK20 is found in less than 20% of PDAC cases (35) . We found that the protein expression profiles of these cytokeratins is maintained in the PDX and organoid models (Figure 2, Figure S2 ). We also examined nuclear labeling of the mutated tumor suppressor p53, as aberrant expression occurs in at least 70% of PDAC (31, 36) .
Consistent with these previous observations, we found that normal pancreatic epithelium showed low levels of p53 expression while p53 is increased in primary tumors and corresponding PDX and organoid models (Figure 2) . We also stained for Claudin-4, which is often overexpressed in PDAC (37) (38), and we observed that its pattern of overexpression is elevated in both PDX and organoids models (Figure 2) . Next, we examined tumor epithelial cells for the expression of the sialyl Lewis motif that corresponds to CA19-9 (39). We found that all of the primary tumors studied expressed CA19-9, and that both the PDX and organoid models stained positive for CA19-9 as well. In normal pancreatic epithelium, we saw that CA19-9 was restricted to the luminal surface. However, in tumor cells, the antigen was localized in the cytoplasm, basolateral membrane, and occasionally at the apical cell membrane. In addition, the staining intensity was increased in tumor cells compared with normal epithelium (40) (Figure 2) . Finally, we investigated the expression of CEA, which has been reported to have positive staining in PDAC (41) . We observed positive staining in the tumor group, as well as the PDX and organoid models ( Figure S2 ). In summary, we observed a strong concordance of expression between the primary tumor, organoid and PDX models for all the protein biomarkers examined.
DNA and RNA sequencing demonstrates molecular profiles common to primary tumor,
PDX and organoid models
We next investigated if PDX and organoid models preserve the genomic and transcriptomic characteristics of their corresponding tumors. We extracted DNA from the between the three models and the tumor sample ( Figure 4B ). Furthermore, a majority of differentially-expressed genes are similarly up-or down-regulated across all models in comparison to the primary tumor ( Figure 4D ). Functional analysis of differentially expressed genes indicated that proliferation and cancer-related genes are upregulated across primary tumor and models when compared to normal, whereas some models show decreased expression of invasion-related genes ( Figure 4C) . Overall, we observed that 2D and 3D models maintain much of the gene expression that contributes to tumor phenotypes, although differences are apparent.
Single cell RNA-seq reveals transcriptionally distinct subpopulations within organoids
To understand the cellular composition of the organoid models, we performed high throughput single cell RNA-seq using the Drop-seq platform (24) . We sequenced the transcriptomes of 7,675 single cells derived from organoids (patient 1). We detected a median of 417 genes per cell (mean 715 genes per cell) at an average sequencing depth of ~20,000 reads per cell ( Figure 5A ).
We first compared Drop-seq measurements to the bulk RNA-seq data discussed above, and found the data were correlated (R squared: 0.65) ( Figure 5B ). We then clustered the single cell transcriptional results to identify distinct subgroups of cells, using a computational approach 
Organoids demonstrate differential responses to drug treatments
To determine if PDX-and primary tumor-derived organoid models can be used for drug response assays, we tested organoids for dosage dependent and drug-specific responses and investigated if organoid drug responses could recapitulate PDX results.
We treated organoids with gemcitabine, a chemotherapeutic agent used in PDAC, and measured resulting levels of apoptosis. Specifically, PDX-derived organoids (patient 1) were treated with three different concentrations of gemcitabine (3nM, 10nM, 30nM) for 72 hours and apoptosis was measured in real-time (Movie S1). Treatments caused a dose-dependent apoptotic response to gemcitabine (P =0.003 for 10nM, P=0.009 for 30nM, 3nM not significant) ( Figure   6A ). To determine whether primary tumor-derived organoid samples would yield similar results, we performed the same apoptosis assay in patient 6. Again, we observed a dose-dependent response, and interestingly, there was a full response to gemcitabine at 10nM indicating that the sensitivity threshold was higher in this sample compared to patient 1 ( Figure 6B ).
To investigate the in vivo drug response to FOLFIRINOX, we utilized a PDX from a patient that became resistant to FOLFIRINOX post-surgery (patient 1, Table S1 ). Following PDX-engraftment, tumor volume was measured over the course of 4 weeks. We did not find a significant benefit of FOLFORINOX treatment ( Figure 6C ). To mimic patient treatments after Overall, these data demonstrated that treatment of PDX-derived organoids recapitulates the effects of in vivo treatments. Therefore, organoids derived from either PDX or primary tumors are not only suitable for drug treatment studies, but results may also reflect patientspecific sensitivities to drugs.
DISCUSSION
Here we have defined the histopathology, genetic heterogeneity and therapeutic sensitivity profiles of organoid models derived from PDAC patients. The results indicate strong concordance at the morphological and molecular levels, and are promising for the development of personalized organoid models that could be used to help guide therapeutic decisions. We have shown that organoids can recapitulate the morphological architecture of the primary tumor of origin. Specifically, we identified three major epithelial growth patterns that are found in the primary tumor and are well reflected in organoid models. These structures include simple, papillary, and cribriform morphologies that can be indicators of degree of tumor differentiation.
The use of protein expression profiles in histopathological classification is used along with structural information to determine tumor type and degree of differentiation. We demonstrated that commonly used protein markers for PDAC analysis are maintained between both organoid and PDX models and primary tumors. Importantly, because organoids can be grown from a fine- In summary, our study has demonstrated that organoids are potentially valuable for drug treatment studies because they maintain distinct phenotypes and therefore respond differently to drug combinations and dosage. These models may allow for ex vivo drug testing of patient samples to steer treatment decisions. Furthermore, these models have potential utility for high throughput drug discovery assays. FHL1_D184E  FHL1_P247S  ALK_D239G  KMT2D_R2460H  SYNE1_E3668*  CDK12_E791Q  EIF4A2_Y349X  NUMA1_A1807T  KRAS_G12D  MAP2K4-chr17_12016679_T->A  TP53_R209X  KRAS_G12V  TP53_R158L  NTRK3_S564C  ATP10A_F425S  PARP1_K221T  ZBTB16_G433R  TCL1A_R52H  TP53_F270L  STAG2_M1162T  EPHB4_GQAH68-71X  EP400_S681P  TP53_F134L  NALCN_R1498C  RNF43_R40X  KRAS_G12R Figure 6 . Patient-derived models respond differentially to chemotherapeutic agents. (A and B) Real-time levels of apoptosis for PDX-derived organoids from patient 1 (A) and tumor-derived organoids from patient 6 (B) were treated with gemcitabine (3nM, 10nM, 30nM). Apoptosis was measured in real-time over 72 hours (% fluorescent green signal, n=4). PDX from patient 1 (as in A), was treated in vivo with FOLFIRINOX (10nM) (C), or gemcitabine (10nM) with or without Abraxane (10nM) (D). Tumors growth (mm3) was measured over 4 weeks. Control mice received vehicle, (n=3). Points are mean tumor volume; bars, SE. (C and D) . The same treatment was applied in vitro to PDX-derived organoids from patient 1. Proliferation was measured by %relatively cell growh/death (E) SE,*p<.001. Representative light microscopy (10x) images at 10nM are shown (right panel). 
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